Cite
HARVARD Citation
Rahmany, S. et al. (n.d.). PTH-157 The Introduction of Biosimilar Infliximab (CT-P13) through A Managed Switching Programme Generates Significant Cost Savings with High Levels of Patient Satisfaction. Gut. p. A297. [Online].